Galvin J, Milam r, patterson b, mepola j, buckwalter j, wolf b, say f, free k, yohannes e

Abstract accepted for platform presentation at the 2024 Society of Military Orthopaedic Surgeons (SOMOS) Annual Meeting

The incremental biological changes in the synovial microenvironment of the shoulder in acute and chronic instability that may contribute to joint degeneration are poorly understood. Proteomic analysis of synovial fluid in patients with shoulder instability may improve our understanding of proteins that are shed into shoulder synovial fluid after an injury.

Proteomic analysis enriched our understanding of proteins that were secreted into shoulder synovial fluid of patients with shoulder instability. The identification of POSTN, a proinflammatory catabolic protein involved with tissue remodeling and repair, as a significant target in anterior shoulder instability is a novel finding. Therefore, further study is warranted to determine the role that POSTN may play in the progression of bone loss and posttraumatic osteoarthritis.

m smith, x yuan, j smith, j banks deal jr, g nanos, s tintle, d reece, m miller

Abstract awarded the Jamie Dianne Bulken-Hoover Memorial- Best Hand Paper at The Society of Military Orthopedic Surgeons Annual Meeting in Nashville, TN- December 2024

Carpal tunnel release (CTR) using a mini-open (mOCTR) or endoscopic approach is the current standard of care (SOC) in the Military Health System (MHS) for management of refractory carpal tunnel syndrome (CTS), the most common peripheral entrapment neuropathy. CTR techniques have evolved over time to reduce iatrogenic tissue trauma and post-operative pain, promoting quicker recovery and improved outcomes. CTR using Ultrasound Guidance (CTR-US) is a promising treatment option under study for military beneficiaries with CTS in a trial comparing outcomes of CTR-US and mOCTR.

This single-site pragmatic randomized controlled feasibility trial at Walter Reed National Military Medical Center (WRNMMC) was approved by the Institutional Review Board (WRNMMC-2020-0278). Military beneficiaries (18-89 years) with clinical, electrodiagnostic, and sonographic findings consistent with CTS were enrolled. Exclusion criteria included prior wrist surgery, median nerve trauma, or sonographic findings precluding safe and effective CTR-US.

Participants were randomized to receive either CTR-US by board-certified Physical Medicine and Rehabilitation physicians with advanced training in ultrasound-guided procedures in a clinic procedure room with local anesthesia, or mOCTR by board-certified Orthopedic Hand Surgeons in a clinic procedure room with local anesthesia or operating room (OR) with moderate sedation. CTR-US was performed under continuous ultrasound guidance with a device featuring inflatable balloons to create space within the carpal tunnel and a retractable blade that releases the transverse carpal ligament in a retrograde manner.

Demographics and patient-reported outcome measures (PROMs) were collected at baseline. Follow-up PROMs were collected at 1, 2, 3, 4, 6 weeks, 3, 6, 12, and 24 months post-procedure. The primary outcome was the Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) at 1 month. Additional outcomes included Boston Carpal Tunnel Questionnaire – Symptom Severity Scale (BCTQ-SS), Numerical Pain Rating Scale (NPRS), Global Assessment of Satisfaction, Global Rating of Change (GROC), modified 2-item CTS Palmar Pain Scale; grip and pinch strength (3 and 12 months); procedure time and incision length; and adverse events. Descriptive analyses reported central tendencies in terms of location (e.g., mean) and scale (e.g., standard deviation) for all study variables. Inferential analyses included two-sample Welch’s T-tests (α = 0.01) for procedural data and complete-case, intention-to-treat, generalized additive models incorporating multi-level structures through patient-level random effects for all other outcomes. No confidence interval (α = 0.05) overlaps on generalized additive models indicated statistical significance.

CTS is the most common peripheral entrapment neuropathy, impacting the health of military beneficiaries. CTS treatment barriers within the MHS include limited access to subspecialty care, lack of resources, and OR procedural costs. Preliminary data from this trial suggest that CTR-US can be performed within a clinic environment by non-operative physicians with advanced training, resulting in decreased post-procedural incisional pain and non-inferior outcomes compared to mOCTR approach out to 2 years. Outcomes of this WRNMMC trial can facilitate expansion of available CTS management options within the MHS, improving access to care and operational readiness.

galvin j, johnson c, say f, free k, eichinger j, patterson b, nepola j, hogue j, dalgard c, colburn z

Abstract accepted at The Society of Military Orthopedic Surgeons 2024 Annual Meeting

Glenoid dysplasia is a rare pathology characterized by failure of development of the posterior glenoid, resulting in severe deformity and alteration of shoulder mechanics. It is largely asymptomatic until approximately 25 to 45 years of age. When patients develop pain, they typically already have severe posterior cartilage wear and early-onset osteoarthritis. Therefore, early detection of glenoid dysplasia may offer an opportunity to intervene in adolescence or counsel patients on their condition so they can modify their activities. The purpose of this study was to identify genetic variants associated with the diagnosis of severe glenoid dysplasia.

Three male patients (mean age: 40.3 yrs, range: 38-43) with severe glenoid dysplasia who underwent blood draw at the time of operative treatment were analyzed. High molecular weight genomic DNA was isolated from the stabilized whole blood before PCR-free sequencing libraries were generated with sufficient yield for downstream sequencing. Whole genome sequencing (WGS) was performed on all 3 patients with genomic data passing quality assessment (QA) after alignment and variant calling (mean coverage >30x, alignment >97%, percent bases 20x >92%). For variant priorization and interpretation, we utilized a phenotype-aware workflow, Genomizer, with the gene ontology HP:0006633 and the parent ontology of “abnormality of the glenoid fossa.” Additionally, we interpreted variants from genes within the American College of Medical Genetics and Genomics (ACMG) v3.2 list, to potentially report actionable secondary findings.

HOXA9,c.715G>A:p.(Val239Met) was identified as a candidate genetic variant in 1 of 3 patients with severe glenoid dysplasia. Prior evidence has implicated the HOX gene in the development of the inferior glenoid ossification center. This information may lead to future precision medicine approaches for early diagnosis and novel treatments. Future larger studies are needed to confirm these findings.